Liquid biopsy: early and accurate diagnosis of brain tumor

Yi, Zhenjie; Qu, Chunrun; Zeng, Yu; Liu, Zhixiong

doi:10.1007/s00432-022-04011-3

Cited by 12 publications

(12 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liquid biopsy requires technology capable of extracting tumor genetic material (DNA or RNA) from the blood, along with a technique that can quantify and characterize the molecular sequence. Nucleic acids can be detected by polymerase chain reaction (PCR)-based techniques or next-generation sequencing (NGS)[ 19 ]. The advantages of PCR-based techniques include their lower cost, shorter processing time, and easier bioinformatics analysis than NGS techniques[ 20 ].…”

Section: Advances In Liquid Biopsy Detection Technologymentioning

confidence: 99%

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Valenzuela¹,

Burotto²,

Marcelain³

et al. 2022

WJGO

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major cause of mortality worldwide, associated with a steadily growing prevalence. Notably, the identification of KRAS , NRAS , and BRAF mutations has markedly improved targeted CRC therapy by affording treatments directed against the epidermal growth factor receptor (EGFR) and other anti-angiogenic therapies. However, the survival benefit conferred by these therapies remains variable and difficult to predict, owing to the high level of molecular heterogeneity among patients with CRC. Although classification into consensus molecular subtypes could optimize response prediction to targeted therapies, the acquisition of resistance mutations to targeted therapy is, in part, responsible for the lack of response in some patients. However, the acquisition of such mutations can induce challenges in clinical practice. The utility of liquid biopsy to detect resistance mutations against anti-EGFR therapy has recently been described. This approach may constitute a new standard in the decision algorithm for targeted CRC therapy.

show abstract

Section: Advances In Liquid Biopsy Detection Technologymentioning

confidence: 99%

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Valenzuela¹,

Burotto²,

Marcelain³

et al. 2022

WJGO

View full text Add to dashboard Cite

show abstract

“…A leading cause of death globally, cancer presents a serious threat to general public health . Currently, most diagnostic techniques rely solely on invasive tissue biopsies, which are unsatisfactory for the detection of early tumors or residual lesions . In an effort to avoid interventional damage and achieve real-time surveillance of early cancer, the development of noninvasive liquid biopsy methods by detecting circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), and exosomes is currently receiving increasing attention from researchers.…”

Section: Introductionmentioning

confidence: 99%

“…1 Currently, most diagnostic techniques rely solely on invasive tissue biopsies, which are unsatisfactory for the detection of early tumors or residual lesions. 2 In an effort to avoid interventional damage and achieve real-time surveillance of early cancer, the development of noninvasive liquid biopsy methods by detecting circulating tumor DNA (ctDNA) 3 and circulating tumor cells (CTCs), 4 and exosomes 5 is currently receiving increasing attention from researchers. ctDNA is cell-free DNA fragments actively released and secreted from apoptotic or necrotic tumor cell debris into the blood system.…”

Section: ■ Introductionmentioning

confidence: 99%

Fe Single-Atom Carbon Dots Nanozyme Collaborated with Nucleic Acid Exonuclease III-Driven DNA Walker Cascade Amplification Strategy for Circulating Tumor DNA Detection

Long,

Zhao,

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

“…The search for a non-invasive test that can give information on the state of the disease, in primary or secondary brain tumors, is the challenge of recent years. Among these, the role of circulating biomarkers in the cerebrospinal fluid, such as circulating tumor DNA, microRNAs and metabolites [ 9 ], and blood biomarkers, the latter being more accessible for easy sampling [ 10 ], emerged in the studies.…”

Section: Introductionmentioning

confidence: 99%

“…Exosomes can be isolated from peripheral blood and miRNAs can be measured by widely used techniques. It has been shown that it is possible to discriminate the exosomes secreted by the tumor that contain the microRNAs and peptides necessary for its growth and survival [ 10 ]. The altered expression levels of some miRNAs, which has been observed in brain tumor tissue, has been also studied as a biomarker to predict survival and response to therapy [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

miRNAs in Serum Exosomes for Differential Diagnosis of Brain Metastases

Catelan

Olioso

Santangelo

et al. 2022

Cancers

View full text Add to dashboard Cite

Circulating miRNAs are increasingly studied and proposed as tumor markers with the aim of investigating their role in monitoring the response to therapy as well as the natural evolution of primary or secondary brain tumors. This study aimed to evaluate the modulation of the expression of three miRNAs, miR-21, miR-222 and miR-124-3p, in the serum exosomes of patients with high-grade gliomas (HGGs) and brain metastases (BMs) to verify their usefulness in the differential diagnosis of brain masses; then, it focused on their variations following the surgical and/or radiosurgical treatment of the BMs. A total of 105 patients with BMs from primary lung or breast cancer, or melanoma underwent neurosurgery or radiosurgery treatment, and 91 patients with HGGs were enrolled, along with 30 healthy controls. A significant increase in miR-21 expression in serum exosomes was observed in both HGGs and BMs compared with healthy controls; on the other hand, miR-124-3p was significantly decreased in BMs, and it was increased in HGGs. After the surgical or radiosurgical treatment of patients with BMs, a significant reduction in miR-21 was noted with both types of treatments. This study identified a signature of exosomal miRNAs that could be useful as a noninvasive complementary analysis both in the differential diagnosis of BMs from glial tumors and in providing information on tumor evolution over time.

show abstract

Liquid biopsy: early and accurate diagnosis of brain tumor

Cited by 12 publications

References 170 publications

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Fe Single-Atom Carbon Dots Nanozyme Collaborated with Nucleic Acid Exonuclease III-Driven DNA Walker Cascade Amplification Strategy for Circulating Tumor DNA Detection

miRNAs in Serum Exosomes for Differential Diagnosis of Brain Metastases

Contact Info

Product

Resources

About